Showing results (121-130 of 660) with videos related to
Sort By:
Pageof 66
Nature Cancer|February 13, 2024
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumorsChristopher J Bergin, Aïcha Zouggar, Amanda Mendes da Silva, et al.Nature Cancer|February 27, 2024
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunityHaojie Dong, Xin He, Lei Zhang, et al.Nature Cancer|June 3, 2024
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic featuresTian-Gen Chang, Yingying Cao, Hannah J Sfreddo, et al.Nature Cancer|April 24, 2024
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trialMeenakshi Hegde, Shoba Navai, Christopher DeRenzo, et al.Nature Cancer|October 2, 2023
Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasiaSamuel F M Hart, Marisa A Yonemitsu, Rachael M Giersch, et al.Nature Cancer|October 2, 2023
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivoEirini Giannakopoulou, Madeleine Lehander, Stina Virding Culleton, et al.Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.Nature Cancer|October 1, 2024
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanismsXin Zhou, Ying Wang, Zhangqi Dou, et al.Nature Cancer|September 26, 2024
Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinomaXinyao Qiu, Tao Zhou, Shuai Li, et al.Nature Cancer|February 24, 2026
The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinationsJohnny X Yu, Jung Min Suh, Katerina D Popova, et al.Pageof 66